Logo image of HRTX

HERON THERAPEUTICS INC (HRTX) Stock Fundamental Analysis

NASDAQ:HRTX - Nasdaq - US4277461020 - Common Stock - Currency: USD

1.29  -0.01 (-0.77%)

Premarket: 1.35 +0.06 (+4.65%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HRTX. HRTX was compared to 549 industry peers in the Biotechnology industry. Both the profitability and financial health of HRTX have multiple concerns. While showing a medium growth rate, HRTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HRTX had negative earnings in the past year.
In the past year HRTX has reported a negative cash flow from operations.
HRTX had negative earnings in each of the past 5 years.
HRTX had a negative operating cash flow in each of the past 5 years.
HRTX Yearly Net Income VS EBIT VS OCF VS FCFHRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

HRTX has a Return On Assets of -3.30%. This is amongst the best in the industry. HRTX outperforms 88.16% of its industry peers.
Industry RankSector Rank
ROA -3.3%
ROE N/A
ROIC N/A
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HRTX Yearly ROA, ROE, ROICHRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 73.97%, HRTX belongs to the top of the industry, outperforming 83.06% of the companies in the same industry.
HRTX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for HRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
HRTX Yearly Profit, Operating, Gross MarginsHRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HRTX has more shares outstanding
HRTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HRTX has been reduced compared to a year ago.
HRTX Yearly Shares OutstandingHRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
HRTX Yearly Total Debt VS Total AssetsHRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

HRTX has an Altman-Z score of -9.72. This is a bad value and indicates that HRTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.72, HRTX is doing worse than 72.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.72
ROIC/WACCN/A
WACC8.57%
HRTX Yearly LT Debt VS Equity VS FCFHRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

HRTX has a Current Ratio of 2.40. This indicates that HRTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.40, HRTX is doing worse than 70.67% of the companies in the same industry.
HRTX has a Quick Ratio of 1.76. This is a normal value and indicates that HRTX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.76, HRTX is not doing good in the industry: 77.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 1.76
HRTX Yearly Current Assets VS Current LiabilitesHRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.75% over the past year.
The Revenue has grown by 13.57% in the past year. This is quite good.
Measured over the past years, HRTX shows a decrease in Revenue. The Revenue has been decreasing by -0.24% on average per year.
EPS 1Y (TTM)93.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%3.26%

3.2 Future

HRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.81% yearly.
HRTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.28% yearly.
EPS Next Y73.56%
EPS Next 2Y66%
EPS Next 3Y63.14%
EPS Next 5Y45.81%
Revenue Next Year12.54%
Revenue Next 2Y12.56%
Revenue Next 3Y13.85%
Revenue Next 5Y15.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HRTX Yearly Revenue VS EstimatesHRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
HRTX Yearly EPS VS EstimatesHRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.
HRTX is valuated rather expensively with a Price/Forward Earnings ratio of 18.97.
Based on the Price/Forward Earnings ratio, HRTX is valued cheaply inside the industry as 92.53% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HRTX to the average of the S&P500 Index (34.98), we can say HRTX is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 18.97
HRTX Price Earnings VS Forward Price EarningsHRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HRTX Per share dataHRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

HRTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HRTX's earnings are expected to grow with 63.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66%
EPS Next 3Y63.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HERON THERAPEUTICS INC

NASDAQ:HRTX (8/19/2025, 8:00:01 PM)

Premarket: 1.35 +0.06 (+4.65%)

1.29

-0.01 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners81.33%
Inst Owner Change4.11%
Ins Owners0.66%
Ins Owner Change6.87%
Market Cap196.80M
Analysts84
Price Target6.38 (394.57%)
Short Float %23.59%
Short Ratio20.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)210.25%
Min EPS beat(2)173.52%
Max EPS beat(2)246.99%
EPS beat(4)3
Avg EPS beat(4)96.3%
Min EPS beat(4)-47.06%
Max EPS beat(4)246.99%
EPS beat(8)6
Avg EPS beat(8)64.69%
EPS beat(12)8
Avg EPS beat(12)43.56%
EPS beat(16)10
Avg EPS beat(16)31.82%
Revenue beat(2)2
Avg Revenue beat(2)4.47%
Min Revenue beat(2)1.93%
Max Revenue beat(2)7%
Revenue beat(4)2
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-12.91%
Max Revenue beat(4)7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)6
Avg Revenue beat(12)0.93%
Revenue beat(16)7
Avg Revenue beat(16)-2.78%
PT rev (1m)0%
PT rev (3m)25%
EPS NQ rev (1m)24.98%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)12.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 18.97
P/S 1.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)0.07
Fwd EY5.27%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.97
BVpS-0.19
TBVpS-0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.97%
FCFM N/A
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.1%
Cap/Sales 1.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 1.76
Altman-Z -9.72
F-Score4
WACC8.57%
ROIC/WACCN/A
Cap/Depr(3y)61.69%
Cap/Depr(5y)104.8%
Cap/Sales(3y)1.37%
Cap/Sales(5y)3.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y73.56%
EPS Next 2Y66%
EPS Next 3Y63.14%
EPS Next 5Y45.81%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%3.26%
Revenue Next Year12.54%
Revenue Next 2Y12.56%
Revenue Next 3Y13.85%
Revenue Next 5Y15.28%
EBIT growth 1Y95.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.89%
OCF growth 3YN/A
OCF growth 5YN/A